(6S,9S,12S,E)-9-tert-butyl-12-isopropyl-2,2,5,11,14-pentamethyl-4,7,10-trioxo-6-(2-phenylpropan-2-yl)-3-oxa-5,8,11-triazapentadec-13-en-15-oic acid | 591750-17-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (6S,9S,12S,E)-9-tert-butyl-12-isopropyl-2,2,5,11,14-pentamethyl-4,7,10-trioxo-6-(2-phenylpropan-2-yl)-3-oxa-5,8,11-triazapentadec-13-en-15-oic acid
• 英文别名: (6S,9S,12S,E)-tert-butyl-11-isopropyl-2,2,5,11,14-pentamethyl-4,7,10-trioxo-6-(2-phenylpropan-2-yl)-3-oxa-5,8,11-triazapentadec-13-en-15-oic acid；N-(tert-butoxycarbonyl)-N,β,β-trimethyl-L-phenylalanine-N-[(3S,4E)-5-carboxy-2-methylhex-4-en-3-yl]- N,3-dimethyl-L-valinamide；N-(tert-butoxycarbonyl)-N,β,β-trimethyl-L-phenylalanine-N-[(3S,4E)-5-carboxy-2-methylhex-4-en-3-yl]-N,3-dimethyl-L-valinamide；(S)-N-tert-butoxycarbonyl-N,β,β-trimethylphenylalanyl-(S)-tert-leucyl-(2E,4S)-N-methyl-4-amino-2,5-dimethylhex-2-enoic acid；Boc-HTI-286-OH；(E,4S)-4-[[(2S)-3,3-dimethyl-2-[[(2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-3-phenylbutanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid
• CAS: 591750-17-3
• 化学式: C₃₂H₅₁N₃O₆
• 分子量: 573.773
• InChiKey: MEMBVXWDWUTPTD-GMUJNDQRSA-N

物化性质

• 沸点：
  723.1±60.0 °C(Predicted)
• 密度：
  1.082±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  41
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (6S,9S,12S,E)-9-tert-butyl-12-isopropyl-2,2,5,11,14-pentamethyl-4,7,10-trioxo-6-(2-phenylpropan-2-yl)-3-oxa-5,8,11-triazapentadec-13-en-15-oic acid 以 乙醚 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 methyl (S)-N,β,β-trimethylphenylalanyl-(S)-tert-leucyl-(2E,4S)-N-methyl-4-amino-2,5-dimethylhex-2-enoate trifluoroacetic acid salt
  参考文献：
  名称：

  Synthesis and Antimitotic/Cytotoxic Activity of Hemiasterlin Analogues

  摘要：

  The antimitotic sponge tripeptide hemiasterlin (1) and a number of structural analogues have been synthesized and evaluated in cell-based assays for both cytotoxic and antimitotic activity in order to explore the SAR for this promising anticancer drug lead. One synthetic analogue, SPA110 (8), showed more potent in vitro cytotoxicty and antimitotic activity than the natural product hemiasterlin (1), and consequently it has been subjected to thorough preclinical evaluation and targeted for clinical evaluation. The details of the synthesis of hemiasterlin (1) and the analogues and a discussion of how their biological activities vary with their structures are presented in this paper.

  DOI：

  10.1021/np020375t
• 作为产物：
  描述：

  N-Boc-L-叔亮氨酸 在 lithium hydroxide 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 3.5h， 生成 (6S,9S,12S,E)-9-tert-butyl-12-isopropyl-2,2,5,11,14-pentamethyl-4,7,10-trioxo-6-(2-phenylpropan-2-yl)-3-oxa-5,8,11-triazapentadec-13-en-15-oic acid
  参考文献：
  名称：

  Synthesis and Antimitotic/Cytotoxic Activity of Hemiasterlin Analogues

  摘要：

  The antimitotic sponge tripeptide hemiasterlin (1) and a number of structural analogues have been synthesized and evaluated in cell-based assays for both cytotoxic and antimitotic activity in order to explore the SAR for this promising anticancer drug lead. One synthetic analogue, SPA110 (8), showed more potent in vitro cytotoxicty and antimitotic activity than the natural product hemiasterlin (1), and consequently it has been subjected to thorough preclinical evaluation and targeted for clinical evaluation. The details of the synthesis of hemiasterlin (1) and the analogues and a discussion of how their biological activities vary with their structures are presented in this paper.

  DOI：

  10.1021/np020375t

文献信息

• [EN] CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME<br/>[FR] COMPOSÉS CYTOTOXIQUES ET ANTIMITOTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CT FOR DRUG RES AND DEV

  公开号：WO2014144871A1

  公开（公告）日：2014-09-18

  Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

  揭示了具有细胞毒性和/或抗有丝分裂活性的化合物。还揭示了与制备和使用这些化合物相关的方法，以及包含这些化合物的药物组合物。还揭示了具有结构的组合物：(T)-(L)-(D)，其中(T)是靶向基团，(L)是可选的连接物，(D)是具有细胞毒性和/或抗有丝分裂活性的化合物。
• [EN] SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES<br/>[FR] SYSTÈMES DE LIAISON CONTENANT UN SULFONAMIDE POUR CONJUGUÉS DE MÉDICAMENTS
  申请人：CT FOR DRUG RES AND DEV

  公开号：WO2015095953A1

  公开（公告）日：2015-07-02

  Sulfonamide-containing linkage systems for release of payload compounds from an attached targeting moiety in drug conjugates. The conjugates have the formula of [(P)-(L)]m-(T), wherein (P) is a payload compound, (L) is a linker, (T) is a targeting moiety and m is an integer from 1- to 10. Also provided are pharmaceutical compositions comprising such conjugates and there use in treating cancer.

  含有磺胺基的连接系统，用于从药物共轭物中的附加靶向基团释放有效成分。这些共轭物的化学式为[(P)-(L)]m-(T)，其中(P)代表有效成分，(L)代表连接剂，(T)代表靶向基团，m为1到10之间的整数。还提供了包含这种共轭物的药物组合物，并用于治疗癌症。
• Conjugates of ligand linker and cytotoxic agent and related composition and methods of use
  申请人：Tarasova I Nadya

  公开号：US20050171014A1

  公开（公告）日：2005-08-04

  A conjugate comprising a ligand, a linker, and a cytotoxic agent, in which the linker is FALA, VLALA, ALAL, ALALA, ChaLALA, ChaChaLAL, NalChaLAL or NalLALA; a composition thereof; a method of delivering a cytotoxic agent in a cell-specific manner; and a method of treating cancer in a mammal.

  一种包含配体、连接剂和细胞毒性药物的共轭物，其中连接剂为FALA、VLALA、ALAL、ALALA、ChaLALA、ChaChaLAL、NalChaLAL或NalLALA；其组合物；以及以细胞特异性方式传递细胞毒性药物的方法；以及治疗哺乳动物癌症的方法。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF PLATINUM-DRUG RESISTANT CANCER
  申请人：ZYMEWORKS INC.

  公开号：US20180193473A1

  公开（公告）日：2018-07-12

  VAR2CSA-drug conjugates for targeting and inhibiting the growth of cancer cells that have developed resistance to a platinum drug and the use of the conjugates in the treatment of platinum drug-resistant cancers. VAR2CSA-drug conjugates (VDCs) comprise a VAR2CSA polypeptide that is capable of binding to oncofetal chondroitin sulfate (ofCS) and one or more toxins having anti-cancer activity conjugated to the VAR2CSA polypeptide, either directly or via a linker.

  VAR2CSA-药物偶联物用于靶向和抑制对铂类药物产生耐药性的癌细胞的生长，并将该偶联物用于铂类药物耐药性癌症的治疗。VAR2CSA-药物偶联物（VDCs）包括一个VAR2CSA多肽，能够结合到胎儿骨软骨硫酸酯（ofCS），以及一个或多个具有抗癌活性的毒素，通过直接或通过连接剂与VAR2CSA多肽结合。
• Hemiasterlin Derivative Having Cysteine Residue
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20220144889A1

  公开（公告）日：2022-05-12

  A compound represented by formula (1): wherein b represents an integer of 1 to 5; X represents —NH— or —CO—; Z represents a group represented, for example, by formula (Z-1); R 1 represents a hydrogen atom or (AB) m ; AB represents a particular amino acid residue, and when there is a plurality of ABs, each AB may be the same as or different from each other and ABs are bonded to each other via an amide bond; m represents an integer of 1 to 9; R 2 represents a hydroxy group or (AC) g ; AC represents a particular amino acid residue, and when there is a plurality of ACs, each AC may be the same as or different from each other and ACs are bonded to each other via an amide bond; and g represents an integer of 1 to 9, or a salt thereof.

  化合物的化学式为（1）：其中b表示1至5的整数；X表示—NH—或—CO—；Z表示由化学式（Z-1）表示的基团；R1表示氢原子或(AB)m；AB表示特定的氨基酸残基，当存在多个AB时，每个AB可以相同或不同，并且AB通过酰胺键相互连接；m表示1至9的整数；R2表示羟基或(AC)g；AC表示特定的氨基酸残基，当存在多个AC时，每个AC可以相同或不同，并且AC通过酰胺键相互连接；g表示1至9的整数；或其盐。